Jung, S., Hackenbruch, C., Bauer, J., Heitmann, J. S., Maringer, Y., Oezbek, M. T., Nelde, A., Denk, M., Zieschang, L., Kammer, C., Missios, P., Bonzheim, I., Ebinger, M., Salih, H. R., Bitzer, M., Walz, J. S. (2026). FusionVAC22_02, a phase I clinical trial in progress: Adjuvant
                    <i>DNAJB1-PRKACA</i>
                    fusion transcript–based peptide T-cell activator for fibrolamellar hepatocellular carcinoma (FLC) and other tumor entities carrying the oncogenic driver fusion.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps4270